Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Alaunos Therapeutics Inc TCRT

Healthcare Biotechnology

Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity... see more

Add To Watchlist

Recent & Breaking News (NDAQ:TCRT)

ZIOPHARM to Present at the Stifel 2017 Healthcare Conference

GlobeNewswire November 10, 2017

9 Notable Biotechs Presenting At This Year's ASH Meeting

Benzinga.com November 6, 2017

ZIOPHARM Oncology Reports Third Quarter 2017 Financial Results and Provides Update on Recent Activities

GlobeNewswire November 6, 2017

ZIOPHARM Oncology, Inc. to Host Earnings Call

Accesswire November 6, 2017

ZIOPHARM Announces Four Presentation Abstracts at the 2017 Annual Meeting of the Society for Neuro-Oncology

GlobeNewswire November 6, 2017

ZIOPHARM Announces Five Abstracts Accepted for Presentation at the 2017 American Society of Hematology Annual Meeting

GlobeNewswire November 1, 2017

ZIOPHARM Oncology to Host Third-Quarter 2017 Financial Results and Corporate Update Conference Call on November 6, 2017 at 4:30 p.m. ET

GlobeNewswire October 26, 2017

ZIOPHARM Oncology Announces First Patient Dosed in New Phase 1 Study of Ad-RTS-hIL-12 plus Veledimex for the Treatment of Pediatric Brain Tumors

GlobeNewswire October 16, 2017

Watch These 8 Huge Put Purchases In Friday Trade

Benzinga.com October 13, 2017

ZIOPHARM Announces Three Presentations at the 2017 Annual Meeting of the Society for Neuro-Oncology

GlobeNewswire October 12, 2017

ZIOPHARM Oncology Appoints David Mauney, M.D., as Executive Vice President and Chief Business Officer

GlobeNewswire September 28, 2017

ZIOPHARM Oncology Announces Updated Findings from Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma Presented at American Academy of Neurological Surgery Annual Meeting

GlobeNewswire September 18, 2017

Technical Snapshots for These Biotech Stocks -- ZIOPHARM Oncology, Zosano Pharma, Juno Therapeutics, and Lexicon Pharma

PR Newswire September 7, 2017

ZIOPHARM to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

GlobeNewswire September 5, 2017

ZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit

GlobeNewswire September 1, 2017

ZIOPHARM Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Recent Activities

GlobeNewswire July 31, 2017

Investor Network: ZIOPHARM Oncology, Inc. to Host Earnings Call

Accesswire July 31, 2017

ZIOPHARM Oncology to Host Second-Quarter 2017 Financial Results and Corporate Update Conference Call on July 31, 2017 at 4:30 p.m. ET

GlobeNewswire July 24, 2017

ZIOPHARM Oncology Announces Initiation of Stereotactic Treatment Cohort in Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma

GlobeNewswire June 28, 2017

12 Biggest Mid-Day Gainers For Thursday

Benzinga.com June 22, 2017